Tenaya Therapeutics, Inc. TNYA
Set alert
0.38 USD +0.01 +2.48%
As of Nov 2, 10:27 AM ET
0.3678 Day range 0.3811
0.36 52-week range 1.56
- YTD
- -47.12%
- 1 year
- -73.85%
- Open
- 0.38
- Prev close
- 0.3674
- Mkt cap
- 85.59M
- Vol
- 800.53K
- Avg vol
- 2.78M
- EPS
- -0.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3678
- High
- 0.3811
- Forward P/E
- -1.28
- Beta
- 2.35
- Short ratio
- 2.31
- Inst. own
- 73.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.40
- 200-d avg
- 3.26
- 1y target
- 18.50
2Y chart
Events in this range
- Nov 6, 2024Earnings: -0.3; estimate -0.37; surprise 18.92%
- Nov 7, 2024Rating: Chardan Capital · Buy → Buy
- Nov 25, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 26, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 18, 2024Rating: Chardan Capital · Buy → Buy
Signals (74)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| SMA: Bearish | Mar 25, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 5, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 5, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| RSI: Oversold | Dec 23, 2025 | 10 months ago |
| SMA: Bearish | Dec 12, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 12, 2025 | 10 months ago |
| RSI: Oversold | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| RSI: Overbought | Oct 14, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| RSI: Overbought | Sep 26, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 4, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 27, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| RSI: Overbought | Aug 14, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| RSI: Overbought | Jul 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| RSI: Overbought | Jun 6, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| RSI: Oversold | Mar 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| RSI: Oversold | Jan 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
Key statistics
- Market cap
- 125.96M
- Enterprise value
- 67.37M
- Trailing P/E
- 0.00
- Forward P/E
- -1.28
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.12
- EPS (TTM)
- -1.44
- Beta
- 2.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -56.52M
- Total cash
- 79.47M
- Total debt
- 14.54M
- Return on equity
- -84.49%
- Shares outstanding
- 79.22M
- Short % of float
- 25.39%
- 50-day average
- 2.40
- 200-day average
- 3.26
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.50 +4813.7% upside
Now 0.3765
- Target (low)
- 6.00
- Target (mean)
- 18.50
- Target (high)
- 40.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.315.
Financials — quick view
TNYA Revenue — quarterly 1.11M
TNYA Net income — quarterly -43.39M
TNYA EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.37 | -0.30 | +0.07 | +18.92% |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | -0.34 | +0.06 | +15.00% |
| May 14, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.43 | -0.40 | +0.03 | +6.98% |
| Mar 18, 2024 | Dec 1, 2023 | -0.45 | -0.40 | +0.05 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 18, 2024 | Canaccord Genuity | main | Buy | Buy |
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenayatherapeutics.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
- Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
- Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201
- Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
- Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
- Earnings Scheduled For May 6, 2026
- Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate
- Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation
Your note
Sign in to keep a note on TNYA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI FARAZ | Chief Executive Officer | Sale | Aug 15, 2024 | 188,331 |
| COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| GOEDDEL DAVID V | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| HOEY TIMOTHY | Officer | Sale | Mar 4, 2024 | 245,346 |
| PATTERSON LEONE D. CPA | Chief Financial Officer | Stock Award(Grant) | Feb 22, 2024 | 95,755 |
| SAITO CHIHIRO | Officer | Sale | Nov 17, 2024 | 60,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Column Group LLC | 11.87% | 9,400,290 | 14.95M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.81% | 6,982,587 | 11.10M | Sep 29, 2024 |
| Casdin Capital, LLC | 8.50% | 6,732,971 | 10.71M | Sep 29, 2024 |
| Blackrock Inc. | 5.18% | 4,106,305 | 6.53M | Sep 29, 2024 |
| Vanguard Group Inc | 4.06% | 3,213,167 | 5.11M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.82% | 3,028,435 | 4.82M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 2.65% | 2,099,086 | 3.34M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.61% | 2,064,246 | 3.28M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.20% | 1,746,113 | 2.78M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.80% | 1,428,719 | 2.27M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.87% | 691,525 | 1.10M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 567,023 | 901.57K | Aug 30, 2024 |